Search
Molecular Partners AG
MOLNAdd to Watchlist
3.980USD
+0.050+1.27%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
149.29MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.27%
5 Days
+4.74%
1 Month
+1.27%
6 Months
-5.69%
Year to Date
-8.69%
1 Year
+6.99%
Key Figures
4.100Open
4.175High
46.74KVolume
LossP/E TTM
33.49P/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
3.930Prev. Close
3.960Low
50.41KTurnover
LossP/E Static
1.70P/B
0.00%Div Yield TTM
-50.73%ROA
5.36052wk High
5.37Volume Ratio
-54.04MNet Profit
37.51MShares
-1.9448EPS TTM
1.07Beta
-59.01%ROE
3.41052wk Low
5.46%Amplitude
100.00%Gross Margin
149.29MMarket Cap
--Reward/Risk
3.12%Risk Rate
TradingKey Stock Score of Molecular Partners AG
Currency: USD Updated: 2026-07-02Key Insights
Molecular Partners AG's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 150 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Molecular Partners AG's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Molecular Partners AG Highlights
StrengthsRisks
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Fairly Valued
The company’s latest PE is -2.05, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.59M shares, decreasing 0.34% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
13.000
Target Price
+230.79%
Upside Space
Molecular Partners AG News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Molecular Partners AG Info
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Ticker SymbolMOLN
CompanyMolecular Partners AG
CEOAmstutz (Patrick)
Websitehttps://www.molecularpartners.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Molecular Partners AG (MOLN)?
The current price of Molecular Partners AG (MOLN) is 3.98.
What is the symbol of Molecular Partners AG?
The ticker symbol of Molecular Partners AG is MOLN.
What is the 52-week high of Molecular Partners AG?
The 52-week high of Molecular Partners AG is 5.36.
What is the 52-week low of Molecular Partners AG?
The 52-week low of Molecular Partners AG is 3.41.
What is the market capitalization of Molecular Partners AG?
The market capitalization of Molecular Partners AG is 149.29M.
Is Molecular Partners AG (MOLN) currently rated as Buy, Hold, or Sell?
According to analysts, Molecular Partners AG (MOLN) has an overall rating of Buy, with a price target of 13.00.
What is the Earnings Per Share (EPS TTM) of Molecular Partners AG (MOLN)?
The Earnings Per Share (EPS TTM) of Molecular Partners AG (MOLN) is -2.09.